Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines

A Vogel¹, E Martinelli²; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org; ESMO Guidelines Committee

Collaborators, Affiliations

Collaborators

A Vogel, A Cervantes, I Chau, B Daniele, J M Llovet, T Meyer, J-C Nault, U Neumann, J Ricke, B Sangro, P Schirmacher, C Verslype, C J Zech, D Arnold, E Martinelli

Affiliations

¹ Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany.
² Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy.

PMID: 33716105
DOI: 10.1016/j.annonc.2021.02.014

Free article

Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines

A Vogel et al. Ann Oncol. 2021 Jun.

Free article

. 2021 Jun;32(6):801-805.

doi: 10.1016/j.annonc.2021.02.014. Epub 2021 Mar 5.

Authors

A Vogel¹, E Martinelli²; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org; ESMO Guidelines Committee

Collaborators

A Vogel, A Cervantes, I Chau, B Daniele, J M Llovet, T Meyer, J-C Nault, U Neumann, J Ricke, B Sangro, P Schirmacher, C Verslype, C J Zech, D Arnold, E Martinelli

Affiliations

¹ Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany.
² Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy.

PMID: 33716105
DOI: 10.1016/j.annonc.2021.02.014

No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure AV reports invited speaker roles for Roche, Sanofi, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, EISAI, IPSEN, INCYTE, Pierre Fabre, Delcath, Lilly and Advisory Boards for Roche, Bayer, Bristol Myers Squibb, Merck Sharp & Dohme, EISAI, IPSEN, INCYTE, Pierre Fabre, BTG, Lilly, AstraZeneca and Merck. EM has received honoraria for lecture and advisory boards from Roche, Amgen, Servier, Astra Zeneca, Bayer, Merck-Serono, Pierre Fabre and Sanofi, and grant support from AIRC and speaker support from ESMO.

Cited by

Long-Term Survival in Hepatocellular Carcinoma following Second-Line Tumor Treating Fields Therapy and Sorafenib: A Case Report.
Torres Velasco M, Álvarez Gallego R, Peinado P, Muñoz Gregorio C, Ugidos L, García Morillo M, Vicente E, Quijano Y, Prados S, de la Fuente E, Cubillo Gracián A. Torres Velasco M, et al. Case Rep Oncol. 2024 Jul 31;17(1):843-851. doi: 10.1159/000539719. eCollection 2024 Jan-Dec. Case Rep Oncol. 2024. PMID: 39144246 Free PMC article.
Exploring the Evolving Landscape of Stereotactic Body Radiation Therapy in Hepatocellular Carcinoma.
Sharma D, Khosla D, Meena BL, Yadav HP, Kapoor R. Sharma D, et al. J Clin Exp Hepatol. 2025 Jan-Feb;15(1):102386. doi: 10.1016/j.jceh.2024.102386. Epub 2024 Aug 3. J Clin Exp Hepatol. 2025. PMID: 39282593 Review.
Synergistic Pro-Apoptotic Effect of a Cyclic RGD Peptide-Conjugated Magnetic Mesoporous Therapeutic Nanosystem on Hepatocellular Carcinoma HepG2 Cells.
Zhao X, Liu C, Wang Z, Zhao Y, Chen X, Tao H, Chen H, Wang X, Duan S. Zhao X, et al. Pharmaceutics. 2023 Jan 13;15(1):276. doi: 10.3390/pharmaceutics15010276. Pharmaceutics. 2023. PMID: 36678904 Free PMC article.
The Role of the NLRP3 Inflammasome in HCC Carcinogenesis and Treatment: Harnessing Innate Immunity.
Papadakos SP, Dedes N, Kouroumalis E, Theocharis S. Papadakos SP, et al. Cancers (Basel). 2022 Jun 27;14(13):3150. doi: 10.3390/cancers14133150. Cancers (Basel). 2022. PMID: 35804922 Free PMC article. Review.
Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study.
Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Shimada N, Kawata K, Kosaka H, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Kaibori M, Iijima H, Hiasa Y, Kumada T; Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Hatanaka T, et al. Hepatol Int. 2022 Oct;16(5):1150-1160. doi: 10.1007/s12072-022-10358-z. Epub 2022 Jun 24. Hepatol Int. 2022. PMID: 35749019

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines

Collaborators

Affiliations

Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines

Authors

Collaborators

Affiliations

Conflict of interest statement

Similar articles

Cited by

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical